Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Indinavir + stavudine is a combination of two antiretroviral drugs used primarily for the treatment of HIV-1 infection. Indinavir is a **HIV protease inhibitor** that blocks the viral enzyme protease, preventing viral replication[2][3]. Stavudine is a **nucleoside reverse transcriptase inhibitor (NRTI)** that inhibits HIV reverse transcriptase by competing with natural nucleosides, leading to termination of DNA chain elongation[1]. This combination is sometimes used as part of a multi-drug regimen for pediatric and adult patients with HIV, commonly in combination with a third agent such as didanosine, and is designed to suppress plasma HIV RNA and improve immunological status[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on indinavir + stavudine.